Clinical Trials

7 enrolled 9 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06194448 2026-03-06

NEOLA

76 enrolled

Lung Neoplasms

NCT05526755 2026-03-04

TARGET

188 enrolled

Stage II-IIIB Non-small Cell Lung Carcinoma

NCT03940703 2026-02-27

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

140 enrolled 47 charts

Carcinoma, Non-Small-Cell Lung

NCT04606771 2026-02-27

CoC

30 enrolled 20 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06741085 2026-02-18

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

56 enrolled

Non Small Cell Lung Cancer Metastatic

NCT07379476 2026-02-12

Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

64 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03778229 2026-02-10

SAVANNAH

367 enrolled 32 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT07375316 2026-02-10

A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positvie ctDNA After lead-in Osimertinib Monotherapy

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03133546 2026-02-06

BOOSTER

155 enrolled 23 charts

Non Small Cell Lung Cancer Metastatic

NCT04184921 2026-02-03

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

216 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03040973 2026-02-02

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

29 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05546866 2026-01-27

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

51 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05816252 2026-01-27

MK-2870-003

356 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03392246 2026-01-22

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05089916 2026-01-14

ROSE

42 enrolled

NSCLC

NCT04769388 2026-01-12

FLAME

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02442349 2026-01-09

AURA17

171 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT07329322 2026-01-09

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT07323641 2026-01-07

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT03410043 2025-12-26

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

173 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07295821 2025-12-22

NSCLC

Lung Neoplasms

NCT05801029 2025-12-09

OSTARA

Carcinoma, Non-Small-Cell Lung

NCT05642572 2025-12-05

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

66 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07256509 2025-12-05

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07229729 2025-12-01

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

300 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07058519 2025-11-26

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

250 enrolled

Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)

NCT04410796 2025-11-06

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

571 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03667820 2025-11-04

Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

41 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03909334 2025-10-20

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

160 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05880706 2025-09-19

A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

198 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07177092 2025-09-16

SURGAN-TKI

118 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05773092 2025-09-03

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

30 enrolled

NSCLC

NCT04591002 2025-06-26

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

43 enrolled

Lung Neoplasms

NCT07038460 2025-06-26

NEO-LISI

134 enrolled

Resectable Non-small Cell Lung Cancer

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

423 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT06574347 2025-05-21

KYLIN-2

120 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06498986 2025-05-07

A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06014827 2025-05-04

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

32 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06918782 2025-04-09

Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma

47 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05281406 2025-02-21

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06827145 2025-02-14

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03414814 2025-02-11

Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation

15 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT03433469 2025-01-31

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

27 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT03944772 2025-01-30

ORCHARD

247 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02841579 2025-01-28

AZENT

22 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung

NCT06752408 2024-12-30

ANOTHER

316 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02094261 2024-11-06

AURA2

210 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03769103 2024-10-31

Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC